Reviews

Practical considerations in the delivery of genetic counseling and testing services for inherited cancer predisposition


 

Many professional entities endorse the need to deliver cancer genetics risk assessment (CGRA) services through a multidisciplinary team that includes trained genetics professionals. However, market forces, a lack of regulation of genetic testing, patent laws, cost barriers, and a limited workforce in genetics have resulted in an increasing number of community practitioners who order and interpret genetic testing. In addition, varying state-level laws and licensure requirements for genetic counselors may contribute to the nonuniform delivery of CGRA services across the United States. Those who perform genetic testing without having adequate training or expertise may incur liability risks. Moreover, the patient might not enjoy the maximum benefit of testing at the hands of an inadequately trained individual. In the setting of a limited number of professional who are trained in CGRA and a dearth of education and training resources, it is a challenge to integrate genetic testing services into clinical care. With advances in genomics and the implementation of personalized medicine, the problem will only be magnified, and it is critical that there are more opportunities for high quality education and training in clinical cancer genetics free of commercial bias. Successful strategies for delivering comprehensive CGRA services include academic-community partnerships that focus on collaboration with nongenetics providers or the inclusion of a genetics professional in the community setting as part of multidisciplinary patient care. These approaches can leverage the expertise of genetics professionals while allowing patients to remain in their community and enjoy better access to resources for long-term follow-up care.

*Click on the link to the left for a PDF of the full article.

Recommended Reading

CDC urges doctors to help patients quit smoking
MDedge Hematology and Oncology
Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index
MDedge Hematology and Oncology
Utilization of radiotherapy services by a palliative care unit: pattern and implication
MDedge Hematology and Oncology
Predicting life expectancy in patients with advanced incurable cancer: a review
MDedge Hematology and Oncology
Biomarkers of small intestinal mucosal damage induced by chemotherapy: an emerging role for the 13C sucrose breath test
MDedge Hematology and Oncology
ASCO guidelines for fertility preservation affirm oocyte preservation
MDedge Hematology and Oncology
Oral HPV-related cancer risk not transmitted to sex partners
MDedge Hematology and Oncology
How will sequestration affect American cancer care?
MDedge Hematology and Oncology
Cancer health disparities and risk factors: lessons from a woman with a 20-cm chest wall mass, growing for 2 years
MDedge Hematology and Oncology
Opioid overdose deaths skyrocket in women
MDedge Hematology and Oncology